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Abstract.  The expression of the large chondroitin sul- 
fate proteoglycan versican was studied in human adult 
skin.  For this purpose, bacterial fusion proteins con- 
taining unique portions of the versican core protein 
were prepared.  Polyclonal antibodies against the fusion 
proteins specifically reacted with versican from a pro- 
teoglycan fraction of MG63 osteosarcoma cells. In im- 
munohistochemical  experiments,  the affinity-purified 
antibodies localized versican in the stratum basale of 
the epidermis,  as well as in the papillary and reticular 
layers of the dermis.  An apparent codistribution of 
versican with the various fiber forms of the elastic net- 
work of the dermis suggested an association of versi- 
can with microfibrils.  Both dermal fibroblasts and ker- 
atinocytes expressed versican in culture during active 
cell proliferation.  In line with the observation that 
versican is absent in the suprabasal layers of the 
epidermis where keratinocytes terminally differentiate, 
culture conditions promoting keratinocyte differentia- 
tion induced a down-regulation of versican synthesis. 
In Northern blots versican mRNA could be detected in 
extracts from proliferating keratinocytes and dermal 
fibroblasts. Comparison of RNA preparations  from 
semi-confluent and confluent fibroblast cultures 
demonstrated decreasing amounts of versican mRNA 
at higher cell densities.  This inverse correlation of 
versican expression and cell density was confirmed by 
indirect immunofluorescence staining of cultured 
fibroblasts and keratinocytes. The localization of versi- 
can in the basal zone of the epidermis as well as the 
density dependence of versican in cell cultures suggest 
a general function of versican in cell proliferation 
processes that may not solely be confined to the skin. 
ARGE aggregating proteoglycans  form an integral part of 
the extracellular  matrix  of a  wide range  of tissues 
such as the aorta, brain, cartilage,  placenta, sclera, 
skin, and tendon (for review see references 16, 22, 32). Their 
core  proteins  are  mainly  substituted  with  chondroitin/ 
dermatan  sulfate  side chains  and they are able to interact 
with hyaluronic acid. Although a large amount of biochemi- 
cal data is available for these proteoglycans,  until  recently 
little was known about their structural  relationships.  To date, 
the entire primary structures of three members of this family 
of aggregating  proteoglycans have been determined based 
on their cDNA sequences.  This  includes:  the large  carti- 
lage proteoglycan aggrecan  from rat (10), human  (11), and 
chicken (6) sources, the human fibroblast-derived  versican 
(44) and its chicken homologue PG-M (36), and rat neuro- 
can,  a chondroitin  sulfate proteoglycan expressed  in brain 
(31). The core protein structures of aggrecan,  versican, and 
neurocan are similar,  being composed of link protein-like 
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elements at the amino terminal end, followed by a glycosami- 
noglycan  attachment  region of variable length  and finally 
EGF-like elements,  a lectin-like  domain and a complement 
regulatory protein-like  sequence at the COOH-terminus.  In 
aggrecan, EGF- and complement regulatory protein-like ele- 
ments can be missing  due to alternative  splicing events (1, 
11). Whereas the amino and carboxy-terminal  domains of 
aggrecan,  versican  and  neurocan  show a  high  degree of 
similarity with 40 to 60% identical amino acid residues;  the 
central  portions of the core proteins axe unique. 
Versican was originally  cloned from cDNA libraries de- 
rived from human fetal  lung  fibroblasts  IMR-90 (23) and 
from human placenta (44). A series of cells express versican 
in vitro as judged by Northern blotting.  This  includes,  in 
addition  to IMR-90 fibroblasts,  MG63 osteosarcoma cells 
(23),  skin and gingiva fibroblasts  (20),  and arterial  smooth 
muscle cells (35). Versican has been isolated from the cul- 
ture medium of MG63 cells and of Chinese hamster ovary 
cells transfected  with  the full-length  cDNA.  Experiments 
using  recombinant  versican  demonstrated  a  high  affinity 
binding to hyaiuronic  acid through  its amino-terminal  do- 
main  (25). 
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aluronic  acid, fibronectin,  and type I collagen in vitro (43). 
Fibroblasts in culture secrete two alternative  splice forms of 
PG-M, which differ in the length of the central glycosamino- 
giycan attachment region (36). PG-M is transiently expressed 
during the precartilage  condensation  process in the develop- 
ing limb bud of the chicken, disappearing  with the onset of 
cartilage  matrix deposition (21). Other immunoreactive  tis- 
sues in chicken embryos include aorta, lung, cornea, brain, 
skeletal muscle, and dermis (42). 
Data  on  the  tissue  expression  of human  versican  are 
sparse.  Virtual  identity  of versican  sequences with partial 
amino acid sequences of the 60-kD glial hyaluronate binding 
protein, GHAP, suggested that versican (or at least a portion 
of i0 may be present in nervous tissues (28, 44). The recent 
isolation of a brain chondroitin  sulfate  proteoglycan  with 
NH2-terminal  sequences identical  to versican  supports  this 
notion (29). Versican-like proteins seem to occur in a num- 
ber of other tissues (reviewed in reference 22). However, a 
clear identification  of these proteoglycans  has  been ham- 
pered by the lack of well characterized  antibodies. Extensive 
sequence similarities  between the large aggregating proteo- 
glycans as well as the high degree of  core protein substitution 
with glycosarninoglycans  and N- and O-linked oligosaccha- 
rides make the generation  of monospecific  antibodies  diffi- 
cult. 
We therefore employed a fusion protein strategy to prepare 
polyclonal antibodies  exclusively  recognizing  unique por- 
tions of the versican core protein and used these antibodies 
to study the regulation  of versican expression in human skin 
and on keratinocytes  and dermal fibroblasts  in culture. 
Materials and Methods 
Preparation of  Bacterial Fusion Proteins 
and Fusion Protein Columns 
The bacterial expression system,  including vectors and bacterial strains, 
were kindly provided by Dr.  Dieter Stiiber  (Hoffmann-La  Roche,  Basel, 
Switzerland). Fusion proteins were prepared essentially according to Stii- 
bet et all. (37).  PCR was used to isolate two specific versican eDNA por- 
tions: (a) fragment A included buses 1,335 to 1,967 and (b) fragment D 
bases 5,241 to 6,569 (44). The upper strand oligonucleotide  primers, syn- 
thesized on a 391 DNA Synthesizer (Applied Biosystems, Inc., Foster City, 
CA) included at the 5' end two variable nucleotides,  an SflI restriction site, 
the codons for the Factor Xa cleavage sequence, followed by 20 nucleotides 
of versiean sequences.  The lowor strand primers contained two variable 
nueleotides,  a Notl restriction site, an inverse complementary stop codon 
sequence, followed by 20 nucleotides of inverse complementary versican se- 
quences.  Using versican eDNA cloned into pBlueseript (Stratagene,  La 
Jolla, CA) as template,  20 PCR cycles were run on a thermocyeler using 
a PCR amplification  kit (Perkin-Elmer,  Norwalk,  CT). The cycling condi- 
tions consisted of a denaturing step at 94°C for 1 win, primer annealing 
at 55°C for 1 rain and an extension for 4 rain at 72°C.  The final extension 
was prolonged to 10 win. All reactions wore performed in a volume of 100 
#i and included 1 rig of the starting plaswid template.  Resulting fragments 
were digested with SfiI and NotI (Boehriager Mannheim, Maanheim, Ger- 
many), run on agarose gels, electroeluted and subcloned in the SfiI/NotI re- 
striction sites of the expression vector.  For this purpose, we first modified 
the expression vector pDS56/RBSII,6xHis  (= pDS9) by ligating a synthetic 
cassette containing an Sill and a NotI site between the BamHI and PstI sites 
(pDS9-Cassette)  (Fig.  1). The resulting constructs were sequenced over the 
ligation sites to confirm correct in frame cloning of the versican fragments. 
Constructs were transformed into MI5LoREP4]  cells.  Transformed cells 
were grown in LB medium containing 100/tg/ml ampicillin and 25/~g/rni 
kanamycin.  Expression of the fusion proteins was induced by the addition 
of isopropyl-/~-~thiogalactopyranoside  (Boehringer Mannheim) to a final 
concentration  of 2 raM. 5 h after induction, cells were spun down at 6,000 g 
Figure I.  Strategy used for the preparation of bacterial expression 
constructs. RBS,  ribosomal binding site; to, universal translation 
terminator; Xa, coagulation Factor Xa cleavage site. 
for I0 win and the pellet was extracted  with 6 M guanidine-HCl/100  mM 
sodium phosphate, pH 8.0, for 1 h at room tempernture.  The solution was 
cleared of bacterial debris by centrifugation at 10,000 g for 10 win and the 
supernatant was  directly applied to a  5-ml Ni2+-NTA agarose  (Diagen, 
Diisseldorf,  Germany) affinity column. After washing with 8 M urea/100 
mM sodium phosphate/10 mM Tris, pH 8.0, the fusion proteins were eluted 
stepwise  by lowering  the pH to 6.3  and 5.9. Fractions wore analyzed by 
SDS-PAGE and compared with total bacterial extracts prepared by boiling 
bacterial samples in SDS sample buffer. 
For the preparation of bacterial control extracts, M15[pREP4] cells were 
transformed with the expression vector without insert. Propagation,  indue- 
tion, and extraction with 6 M gnanidine or SDS sample buffer wore done 
as  described above.  The gnanidine extract was  dialyzed  against 0.1  M 
NaHCO3/0.5  M NaCI, pH 8.3, precipitated with 3 vol ethanol and lyophi- 
lized. 
Purified fusion proteins A and D as well as the dialyzed gnanidine  extract 
of a control culture were coupled to CNBr-activated  Sepharose 4B (Pharma- 
cia, Uppsala, Sweden)  according to the manufacturer's  instructions. 
Preparation and Purification of  Polyclonal Antibodies 
Fusion proteins A  and D,  respectively,  were  emulsified  in incomplete 
Freund's adjuvant and used to immunize New Zealand white rabbits accord- 
ing to standard protocols (15). 
Antisera were affinity purified  on a Sepharose  4B column (CNBr-acti- 
rated; Pharmacia) coupled with bacterial control extract  followed by ab- 
sorption to the corresponding fusion protein column.  Eluted antibodies 
were precipitated by addition of (NI-I4)2SO4 to 50% saturation and resus- 
pended in TBS/I% BSA/O.02  % sodium azide.  Preimmune control serum 
was treated analogously. 
Cell Cultures 
Keratinocytes  were released from normal human skin by trypsinization and 
cultured in serum-free keratinocyte growth medium (KGM) containing  0.09 
mM calcium (2), 50/~g/ml bovine pituitary extract (BPE), and 5 ng/ml 
recombinant human EGF (GIBCO BRL, Gaithersburg, MD). In experi- 
ments  with higher calcium  concentrations, CaCI2 was  added  into the 
medium  of semieonfluent keratinocyte cultures to yield a final concentration 
of 1.5 mM for the last 48 h prior to immnnostnining. Normal human fibro- 
blasts were grown out of skin explants in DME with 20% FCS, and cultured 
in the same medium with 10% FCS in later passages.  For indirect im- 
munofluorescence  staining experiments,  ceils from the first or second pas- 
sage wore grown on glass cover slips. Keratinocytes were seeded at densities 
varying from 2,000 to 20,000 cells/era  2 and incubated for 4 d, and dermal 
fibroblasts  at densities between 4,000 to 40,000  cells/era  2 and grown for 
2 d prior to staining. 
MG63 osteosarcoma cells (CRL 1427; American Type Culture Collec- 
lion, Rockville,  MD) were grown in IMDM supplemented with 5% FCS, 
1 mM sodium pyruvnte,  100 IU/rnl penicillin, 100 #g/wi streptomycin,  and 
0.5/~g/ml amphotericin (all from GIBCO BRL). 
Isolation of Proteoglycans  from Cell Cultures 
Keratinocytes  and dermal fibroblasts were seeded at a cell density of 3,000 
and 4,000 cells/cm  2, respectively, and grown for 48 h in the corresponding 
media mentioned above. Subsequently, BPE/EGF and serum were removed 
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were prepared by anion exchange chromatography from conditioned me- 
dium and cell layers of  both human  keratinocytes and skin fibroblasts  as well 
as from MG63 osteosarcoma culture medium. In detail, 10 ml Q-Sepharose 
(Pharmacia) per liter and PMSF and sodium azide to final concentrations 
of 1 mM and 0.02  %, respectively, were added to spent medium and in- 
cubated on a shaker at 4"C overnight. After short centrifugation at 500 g, 
the supernatant was removed and the resin was packed into a column. After 
successive washing with 6 M urea/10 mM EDTA/I mM PMSF/Tris, pH 8, 
and with the same buffer containing 0.3 M NaCI, a versican-enriebed frac- 
tion was eluted with 1 M NaCI. 
Cells were extracted with 4 M guanidined50  mM Tris, pH 8, containing 
protease inhibitors (10 mM EDTA, 1 rnM PMSF, 2 ltM leupeptin, and 2 
/tM pepstatin) for 4 h at 4"C. Subsequently,  the guanidine concentration .was 
adjusted to 0.3 M by diluting with 50 mM "Iris, pH 8.0, plus inhibitors. 2 
ml Q-Sepharose was added per 100 ml diluted extract. The subsequent steps 
were performed as described for the medium preparation. 
Fractions containing versican were selected based on immunoreactivity 
in a dot blot, diluted with an equal volume of H20 and precipitated with 
3 vol of ethanol. Chondroitinase ABC (ICN, Costa Mesa, CA) digestions 
were carried out overnight at 37"C, using 2 U/ml of enzyme and 10 ~g/ml 
ovomucoid (Sigma, Buchs, Switzerland) in 40 mM Tris-acetate, pH 8.0. 
Proteoglycan preparations from cell extracts were digested with 10 U//~I 
benzonase (Merck, Darmstadt, Germany) for 1 h at 37°C before the addi- 
tion of chondroitinase ABC. 
Electrophoresis and Immunoblotting 
SDS sample buffer extracts of bacteria and fusion proteins or proteoglycan 
fractions were run under reducing conditions on 12.5 or 4-15% Phastgels 
(Pharmacia), respectively, using SDS-bulfer strips and stained with Coo- 
massie blue or processed for diffusion blotting at 70"C for 20 rain (accord- 
ing to the manufacturer's recommendations). The efficiency  of blotting was 
tested  by  including  prestained  molecular  weight standards  (Bio-Rad 
Laboratories,  Richmond,  CA)  in each  electrophoresis run. Blots were 
blocked with 3% low fat milk in TBS. First antibodies were used 1:1,000. 
The following steps were performed using the ProtoBlot AP Western blot 
detection system (Promega Biotec, Madison, W1). 
~IIssue and Cell Staining 
Immunohistochemical stainings were done on methanol-fixed, 5-/zrn eryo- 
sections of normal human skin using the immunoparoxidase Vectastain 
ABC kit fVector Laboratories, Inc., Burlingame, CA). Incubation with the 
first antibodies was performed at 4"C overnight. The subsequent steps were 
carried out according to the instructions of  the manufacturer. Processed sec- 
tions were counterstained for 1 rain in Mayer's bematoxylin solution. 
In some sections, elastic fibers were stained with resorcin-fuchsin in 
combination with a fast red nuclear stain. 
For indirect immunofluorescenee experiments, cells were fixed and per- 
meab'dized  in methanol for 15 rain at -20"C First antibody incubation was 
done at room temperature overnight. F1TC-labeled anti-rabbit antibodies 
(Dakopatts, Glostrup, Denmark) were used as second antibodies. 
RNA Isolation and Northern Hybridization 
Total RNA was isolated from cultured keratinocytes and skin fibroblasts as 
described by Chomczinski and Saeehi (7). 5 and 20/~g total RNA were run 
on 0.8% agerose-formaldehyde  gels, transferred to C-eneSereen  Plus nylon 
filters (New England Nuclear, Boston, MA) and UV cross-linked. Amounts 
of loaded RNA and integrity of the samples were verified by staining with 
0.04% methylene blue in 0.5 M sodium acetate, pH 5.2 (17). Versican- 
specific RNAs were detected with a digoxygenJa-labeled  anti-sense ribo- 
probe covering bases 2,342  to 4,462  of the versican eDNA (44).  The 
riboprobe was prepared from a pBluescript KS construct with a DIG RNA 
labeling kit using T7 RNA polymera~ (Boehringer Maanheim). Blocking, 
hybridization, washing, and color detection were carried out according to 
the manufacturer's recommendations. 
Results 
Expression of Versican Core Protein Fragments 
in Bacteria 
Two unique portions of the human versican core protein were 
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Figure 2. Localization of versican core protein sequences A and D 
(shaded areas) used  for  antibody preparation.  Versiean model 
modified from reference 44. 
chosen for the preparation of fusion proteins in a  bacterial 
expression system (Fig. 2).  Usually, 1 liter of bacterial cul- 
ture yielded between 3  and 10 nag of versican fragments A 
or D, which could be isolated from cell extracts by affinity 
purification on a metal chelating column charged with nickel 
(Fig. 3).  This resin specifically binds with high affinity to a 
histidine-rich sequence in the leader portion of the fusion 
protein permitting a one-step removal of contaminating bac- 
terial proteins.  The resulting preparations contained more 
than 95 %  pure fusion proteins. 
Polyclonal Antibodies Directed Against Versican 
Fusion Proteins Recognize Intact Versican 
Antisera  obtained  from  rabbits  immunized  with  recom- 
binant proteins A or D were strongly reactive with the corre- 
sponding fusion proteins in immunoblots (Fig. 3).  Neither 
bacterial proteins of cells transformed  with pDS9  cassette 
alone nor the amino-terminal fusion sequence were recog- 
nized by the antibodies as antisera directed against one fu- 
sion protein did not cross-react with bacterial extracts con- 
taining the other fusion protein (data not shown). The crude 
antisera were purified on an affinity-column  coupled with ex- 
tracted  protein from bacterial control cultures followed by 
absorption  on  the  corresponding  fusion protein  columns. 
Both polyclonal antibodies, anti-A and anti-D, reacted with 
intact versican,  partially purified from MG63  culture me- 
dium.  On  4-15%  SDS-polyacrylamide  gels,  versican  re- 
Figure  3. Characterization of  polyclonal antibodies specific for ver- 
sican. SDS-extracts of  bacteria expressing A or D fragments of ver- 
sican (EA and Eo) and purified fusion proteins (A and D)  were 
electrophoresed  on  12.5%  SDS-polyacrylamide gels  and either 
stained with Coomassie blue or subjected to Western blotting as in- 
dicated. The immtmoreaetivity of the affinity-purified  antibodies A 
and D was tested on versican in a proteoglycan fraction from MG63 
osteosarcoma  cells.  The  samples  were  separated  on  4-15% 
SDS-polyacrylamide gels either before (-) or after (+) digestion 
with chondroitinase ABC and processed for immunoblotting. The 
molecular masses of standard proteins are indicated in kD. 
Zimmermann  et al. Versican  Expression in Human Skin  819 Figure  4. The immunohistochemical localization  of versican in cryosections of adult human skin using anti-A (d) and anti-D  antibodies 
(b, f, h, j, and l) is compared with resorcin-fuchsin  staining  of the elastic  network (a,  i, and k). Versican is localized in the basal cell 
layer of the epidermis  (b and j), in the hair follicle 0c), and sweat glands  (h),  and in association  with the elastic  fibers in the dermis (b, 
j, and l). The arrowheads  mark co-localization of versican staining  with oxytalan and elaunin  fibers in the papillary layer (i and j). The 
control reactions included: blocking of  the anti-D immunoreaction by addition of  50 ~g/ml fusion protein D (c) or replacing the first antibody 
with preimmune serum (e and g). Micrographs m to t show indirect immunofluorescence  stainings  of keratinocytes  grown in conditions 
promoting cell proliferation  (m and n) or terminal  differentiation  (o and p) and of dermal fibroblasts  (q and r) using  anti-A (m, o, and 
q) and anti-D antibodies  (n, p, and r) or preimmune serum (s and t). Bars,  50/~m. 
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droitinase ABC,  two bands  with molecular masses larger 
than 300 kD were recognized by both polyclonai antibodies 
(Fig. 3). 
Versican Is a Component of  the 
Dermal-Epidermal Interface 
Immunostaining of normal human skin with both versican- 
specific antibodies  A  and  D  exhibited a  similar,  distinct 
staining pattern, although the antibodies against the A frag- 
ment regularly produced a  weaker signal.  Staining of the 
basal keratinocytes in the interfollicular epidermis, hair fol- 
licles, and sweat glands was prominent (Fig. 4, b, d, f, and 
h). In the epidermis, one to two basal keratinocyte layers dis- 
played a diffuse pattern of the immunoreaction product, with 
the basolateral aspect of the cells staining most strongly. It 
was  not  evident  whether  the  basement  membrane  itself 
stained positive. Trials to split the basement membrane zone 
through the lamina densa using neutral buffers containing 
1 M NaC1 (12) were successful in inducing dermal-epidermal 
separation,  but simultaneously the high salt buffer eluted 
versican from the skin specimen abolishing the immunoreac- 
tion. Other splitting methods, such as incubation of the skin 
at 60°C, destroyed both the structure of dermal-epidermal 
junction and the versican epitopes, thus precluding a defini- 
tive evaluation. 
In the dermis, papillary and reticular fibrillar networks 
stained positive with anti-versican antibodies (Fig. 4, b, j, 
and l). The patterns of the dermal networks closely resem- 
bled those obtained with resorcin-fuchsin (Fig. 4, a, i, and 
k), a stain used in traditional histology to discern the elastic 
fibers in the reticular dermis and the so called elaunin and 
oxytalan fibers in the papillary layer (9). The immunoreac- 
rive fibrils in the reticular dermis were of large diameter run- 
ning mostly parallel to the skin surface (Fig. 4 l). Another 
kind of immunoreactive fibrillar structure,  thinner in di- 
ameter,  originated from these thick fibers.  Vertically ar- 
ranged to the surface of the skin,  they entered the upper 
dermis, fanning out into thin branches that inserted into the 
basement membrane (Fig. 4 j). 
The specificity of the immunoreaction was demonstrated 
by control stainings with preimmnne sera (Fig. 4, e and g) 
and competitive inhibition of the binding of antibodies to tis- 
sue epitopes with the corresponding fusion proteins in solu- 
tion. Addition of 50 #g/ml of fusion protein D to the anti-D 
antibodies completely abolished the positive immunoreac- 
tion in the tissue (Fig.  4  c),  whereas  addition of similar 
amounts of fusion protein A had no effect on the binding of 
anti-D antibodies (not shown). 
Keratinocytes  and l~broblasts  Synthesize Versican In 
Vitro: Evidence for an Association of the Expression 
with Cell Density 
Normal human keratinocytes were first cultured under con- 
ditions that support proliferation but not differentiation (2), 
using a low calcium concentration of 0.09 raM. Under these 
conditions the cells strongly expressed versican as assessed 
by immunofluorescence staining with antibodies A  and D 
(Fig. 4, m and n).  An intracellular, diffuse staining in the 
keratinocytes was  observed.  However,  when the calcium 
concentration in the culture medium was increased to  1.5 
Figure 5.  Detection of versi- 
can  in  cell  layer  (C)  and 
medium fraction (M) of der- 
mal fibroblasts and keratino- 
cytes, comparison with versi- 
can from MG63 osteosarcoma 
cells. Proteoglycan prepara- 
tions were electrophoresed  on 
4-15%  SDS-PAGE and  sub- 
jected to immunoblotting  with 
antibodies against the D frag- 
ment.  The  concentration of 
versican in the samples has been adjusted to yield similar signal in- 
tensities (dilution factors: 3 x  and 80x for the fibroblast cell layer 
and medium fraction, respectively; keratinocyte fractions are both 
undiluted). The molecular masses of standard proteins are indi- 
cated in kD. 
mM, a condition that induces terminal differentiation of the 
keratinocytes (2), versican expression was turned off  (Fig. 4, 
o and p).  Aggregated, stratifying, and differentiating cells 
stained wcaldy, but individual keratinocytes growing next to 
the stratifying islands were negative. 
Similarly to keratinocytes in culture, human skin fibro- 
blasts synthesized  versican in vitro, exhibiting a diffuse  intra- 
cellular or  pericellular  staining but without a  detectable 
deposition in the extracellular space (Fig. 4, q and r). Since 
the lack of deposition might be due to diffusion of the pro- 
teoglycan into the culture medium, immunoblotting experi- 
ments on cell layer extracts and medium fractions of  cultured 
human keratinocytes and dermal fibroblasts were performed. 
Human skin fibroblasts and keratinocytcs in low calcium 
medium both secreted versican into the culture medium as 
demonstrated on immunoblots (Fig. 5). For semi-quantitative 
analysis,  the  dilutions  of the  versican-enriched  fractions 
were adjusted, in order to give bands of similar intensities 
on immunoblots. The comparison of the cell layer and me- 
dium fractions of cultured dermal fibroblasts revealed that 
only a very small amount of versican was retained in the cell 
layer fraction. In contrast, roughly equivalent quantifies of 
versican could be isolated from cell layer and medium of  ker- 
atinocytes grown under culture conditions promoting cell 
proliferation. In general, fibroblasts expressed considerably 
more versican than keratinocytes. Unlike the conditioned 
medium of MG-63 cells, where two bands were recognized 
in  immunoblots  by  the  versican-specific antibodies  after 
chondroitinase ABC digestion, the cell layer and medium 
fractions  of keratinocytes and  skin  fibroblasts  contained 
mainly the lower molecular mass component (Fig. 5).  No 
difference between experiments performed with anti-D and 
anti-A antibodies were observed (not shown). All proteogly- 
can  fractions  used  in  the  immunoblot experiments  were 
derived from semi- to subconfluent cultures, as confluent 
cultures of  keratinocytes, in particular, yielded barely detect- 
able amounts of versican. 
In  Northern  blots,  versican-specific  mRNAs  could  be 
found in total RNA preparations of both keratinocyte and 
fibroblast cultures (Fig. 6). The probe hybridizing to a cen- 
trai, unique portion of  versican recognized two duplex bands 
in the size range of 10 and 12 kb.  Only by increasing the 
amount of total RNA loaded to 20  #g,  versican-specific 
mRNA could be detected in Northern blots of extracts from 
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extracts from dermal fibroblasts and ker- 
atinoeytes on Northern blot.  Total RNA 
preparation from  semi-confluent (a)  and 
confluent (b) fibroblast cultures and from 
keratinocytes, grown at low density under 
conditions permitting cell proliferation (c), 
were separated on 0.8% agarose gels and 
processed for Northern blotting. 5 #g (a 
and b) and 20/zg (c) of total RNA were 
loaded. Internal standard: 28S ribosomal 
RNA  stained  with  methylene blue. The 
sizes of RNA standard molecules are indi- 
cated in kilobases. 
low density keratinocyte cultures (6,300 cells/cm~).  No hy- 
bridiTation  was  observed  in  20  /~g  of total  RNA  from 
confluent keratinocytes grown in either low or high calcium 
medium (not  shown).  In  comparison to  keratinocytes, a 
much higher versican expression was observed in RNA ex- 
tracts of dermal fibroblasts. Semi-confluent fibroblast cul- 
tures  gave stronger versican-specific signals than cells at 
confluency (Fig. 6). 
In line with the results from the Northern blots, the inten- 
sity of ceil stainings with anti-versican antibodies in indirect 
immtmofluorescence experiments correlated inversely with 
the culture density (Fig. 7). Keratinocytes  plated at low den- 
sities revealed a bright immunofluorescenee (Fig. 7 a). With 
the exception of dividing cells, a decreasing immunoreac- 
tivity with versican antibodies was observed in the progres- 
sion to subconfluent (Fig. 7 b) and finally confluent  keratino- 
cyte cultures (Fig. 7 c), the latter staining being only slightly 
above background levels.  A  similar  density dependence, 
however less pronounced, could also be demonstrated in in- 
direct immunofluorescence experiments with dermal fibro- 
blasts in culture (Fig. 7, d-f).  Again, mitotic ceils displayed 
a constantly bright staining signal. 
Discussion 
Versican  belongs to the family of large aggregating proteo- 
glyeans. Other members of  the family, which have been char- 
acterized in terms of their primary structure, are aggrecan 
(I0)  and  neurocan  (3  I).  Shared  features  of  these  three  proteo- 
glycans are a hyaluronic acid  binding domain at  the NH2- 
terminal end and EGF-Iike, lectin-like,  and complement- 
regulatory protein-like  sequences  in the COOH-terminal 
portion  of  the  core  protein.  The intermediate  stretches  of  the 
core  proteins  are  unique  in  each  of  these  proteoglycans.  Due 
to  the  extensive  sequence similarities  in  the  amino- and  car- 
boxy-terminal  domains of  versican,  aggrecan,  and  neurocan, 
and due to  the  high  degree of  carbohydrate substitution,  we 
expected that antibodies generated by immunization with na- 
tive versican would recognize epitopes shared with other pro- 
teoglycans and glycoproteins. To avoid such cross-reactivity, 
specific fragments of  the versican core protein were prepared 
in a bacterial expression system. This way antigenic sites 
could be restricted to sequences unique to versican. In addi- 
tion, two core protein portions with a low probability for at- 
tachraent of glycosaminoglycan  side chains were chosen, in 
order  to  minimize potential blocking of antibody access 
through sterical hindrance. 
Both afffinity-purified antibodies against the A or D frag- 
ment reacted with intact versican in inun~oblots of a proteo- 
glycan-enriched fraction isolated from MG63 culture me- 
dinm.  After chondroitinase ABC digestion the antibodies 
revealed two high molecular mass core proteins. The two 
bands most likely reflect versican isoforms generated by alter- 
native splicing events,  as two duplex bands in the range of 
10 and 12 kb can be detected in Northern blots. The duplex 
patterns observed for both putative splice forms may originate 
from alternative polyadenylation  sites, as the original versi- 
can eDNA sequence contained a polyadenylation  signal 350- 
bp upstream of the 3' end, but no poly-A tail (23).  Further 
evidence for the existence of  alternative splice forms of  versi- 
can is provided by recent data of Shinomura and co-workers 
(36), who have sequenced the entire eDNA of  two splice var- 
iants of PG-M, the chicken analogue of versican. Based on 
sequence similarities, the published versican sequence cor- 
responds to the shorter splice product of PG-M (36). eDNA 
cloning of the long version of human versiean is currently 
under way in our laboratory. 
Both  affinity-purified  antibodies specific for  versican 
could be used for immunohistochemical  staining  experi- 
ments on cryostat  sections.  Although polyclonal  antibodies 
against  the  D fragment gave consistently  a  more intense  sig- 
nal  than antibodies against fragment A, no differences in the 
actual staining patterns were observed. In human skin the 
antibodies revealed an apparent co-localization of versican 
with the  elastic  network of  the dermis. Versican seemed to 
be associated  with all  three  components of  the  elastic  fiber 
system: oxytalan, elaunin,  and elastic  fibers  (9).  The thin 
oxytalan fibers  are arranged  perpendicularly to the der- 
mal-epidermal  junction. They  branch  out  from  elaunin 
fibers  and intersect  the basal lamina. Mainly thick  elastic 
fibers  are  observed in  the  reticular  layer  of  the  dermis. Both 
elastic  and to  a  lesser  extent  also  elaunin  fibers  consist  of  an 
amorphous core  of  insoluble  polymeric elastin  covered with 
bundles of 10-12-nm thick  microfibrils.  Lacking the amor- 
phous elastin  core,  oxytalan fibers  are composed solely  of 
microfibrils (24). As anti-versican antibodies also stain tis- 
sue structures strongly resembling oxytalan fibers, an as- 
sociation with microfibrils appears very likely. Several pro- 
teins have been described to be associated with microfibrils 
(reviewed in reference 27). Among them, fibrillin, a 350-kD 
protein (33) and MAGP, a 31-kD protein (13) seem to be the 
principal  structural  components.  Therefore,  fibrillin and 
MAGP have to be considered prime candidates in the search 
for potential ligands of versican in the elastic network. 
At present, two different large chondroitin/dermatan sul- 
fate proteoglycans have been isolated from skin tissue or 
dermal  fibroblasts  in  culture:  (a)  a  heterodimeric disul- 
fide-bridged proteoglycan with no hyaluronic acid binding 
activity from human embryonic skin fihroblasts (4); and (b) 
a large aggregating proteoglycan derived either from human 
(5,  8,  19,  34),  rat (14) or chicken sources (26).  Versican 
seems to be closely related or identical to the second proteo- 
gIycan, as both bind to hyaluronic acid and yield similar core 
protein bands on SDS-polyacrylamide gels after ehondroiti- 
nase ABC digestion (14, 34). Interestingly, embryonic skin 
The Journal of Cell Biology, Volume 124,  1994  822 Figure  7. Immunostainings of keratinocytes (a-c) and fibroblasts (d-f) with anti-D antibodies reveal a decrease in fluorescence signals 
with increasing densities of the cultures. Keratinocytes were seeded at initial densities of 2,000 (a), 10,000 (b) and 20,000 (c) cells/cm  2, 
fibroblasts at densities of 4,000 (d), 12,000 (e), and 40,000 (f) cells/cm  2. The ceils were cultured for 4 d (a-c) or 2 d (d-f) prior to stain- 
ing. Bar, 100 #m. 
fibroblasts express comparable amounts of the two core pro- 
tein forms (34) resembling the pattern obtained from MG63 
osteosarcoma culture medium, whereas the skin fibroblasts 
from adult donors used in our experiments mainly synthesize 
the lower molecular mass form. This variation may be evi- 
dence for a differential expression of  the two versican isoforms 
in normal adult compared to embryonic or tumor tissues. 
Apart from fibroblasts, keratinocytes are also able to ex- 
press versican in vivo and in vitro, as demonstrated by im- 
munohistological techniques, Western and Northern blots. 
Although the cell staining of proliferating keratinocytes in 
culture with antibodies against versican was stronger in com- 
parison to fibroblasts, keratinocytes express relatively smal- 
ler amounts of versican. The difference may be explained by 
the observation that, unlike keratinocytes, fibroblasts mainly 
secrete versican into the culture medium. 
In the epidermis, versican is restricted to the zone of kera- 
tinocyte proliferation suggesting an involvement in growth 
and differentiation of  epidermal cells. Accordingly, only pro- 
liferating keratinocytes in low calcium cultures express ver- 
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entiation seem to down-regulate the production of versiean. 
The actual synthesis rate of versican may be controlled by 
interaction  with  neighboring  keratinocytes  as  a  clear  de- 
crease in versican-specific immunoreactivity with increasing 
cell density was observed. In line with this observation, ver- 
sican mRNAs could only be detected in preparations from 
low density keratinocyte cultures.  However, a clear assess- 
ment of differences in levels of transcription can not be made 
based on the Northern blot experiments, as versican mRNAs 
seem to be present only at very low abundance even in low 
density keratinoeyte cultures. 
Similar to keratinocytes,  the down-regulation of versican 
expression  is  also observed in dermal  fibroblast cultures. 
The substantial decline in versican mRNA levels from semi- 
confluent to confluent cultures can dearly be demonstrated 
on Northern blots. Previous studies, analyzing glycosamino- 
glycans synthesis in kerarinocytes  (30) and fibroblasts (18) 
noted  a  significant  reduction in chondroitin  sulfates  from 
semi-confluent to confluent cultures. This alteration may at 
least partly be attributed to the down-regulation of versican 
core protein expression. 
The search for putative functions of versican should also 
include its high affinity ligand (25), hyaluronan. Hyaluronan 
has been localized in the dermis as well as in the basal and 
spinal layer of the epidermis (39).  Analogous to versican, 
hyaluronan synthesis is inversely correlated with the cell den- 
sity of fibroblast cultures (18). In vivo, cells usually prolif- 
erate in hyaluronan-rich matrices (reviewed in 40 and 41). 
Hyaluronan may be involved in the detachment and rounding 
during mitosis of fibroblasts (3) and eventually also keratino- 
cytes (38). Similarly, we have observed a strong immunoflu- 
orescence signal with versiean antibodies on rounded fibro- 
blasts and keratinoeytes in mitosis. In the epidermis, secretion 
of versican  and hyaluronan by  proliferating  keratinoeytes 
could provide a highly hydrated matrix facilitating upward 
movement of the dividing cells into the suprabasal layers. 
The down-regulation of the versican expression by differen- 
flaring keratinocytes may subsequently allow righter cell sur- 
face  heparan  sulfate  proteoglyean-  and  integrin-mediated 
cell-cell  contacts in the spinal layer of the epidermis. 
Extracellular  matrices  rich  in  versican  and  hyaluronan 
may more generally function as modulators of call prolifera- 
tion and migration. Thus, the association of cell proliferation 
with versican expression by human epidermal  and dermal 
cells could provide a valuable model system,  to study the 
function  of versican  in  other  epithelial  and mesenchymal 
tissues. 
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